Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: A single centre study

Tissue Antigens

Volumn 72, Issue 6, 2008, Pages 549-558

  Hauzenberger, D ^a   Schaffer, M ^a   Ringden O ^a   Hassan, Z ^a   Omazic, B ^a   Mattsson, J ^a   Wikstrom A C ^a   Remberger, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allele mismatch; Haematopoietic stem cell transplantation; Human leucocyte antigen; Matched unrelated donor

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE MISMATCHED DONOR; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MATCHED UNRELATED DONOR; MORTALITY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME; TRANSPLANT RELATED MORTALITY;

ADOLESCENT; ADULT; ALLELES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFANT; MALE; MIDDLE AGED; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55949127695     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2008.01148.x     Document Type: Article

References (52)

1. Ringden O. Immunotherapy by Allogeneic stem cell transplantation. Adv Cancer Res 2007 : 97C : 25 60.
2. Oliansky DM, Appelbaum F, Cassileth PA et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008 : 14 : 137 80.
3. Blume KG, Forman S, Appelbaum F. Thomas' Hematopoietic Cell Transplantation. Oxford : Blackwell Science Ltd, 2004.
4. Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004 : 104 : 1923 30.
5. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007 : 110 : 4576 83.
6. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995 : 86 : 1606 13.
7. Petersdorf EW, Anasetti C, Martin PJ, Hansen JA. Tissue typing in support of unrelated hematopoietic cell transplantation. Tissue Antigens 2003 : 61 : 1 11.
8. Greinix HAT, Fae I, Schneider B et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant 2005 : 35 : 57 62.
9. Chalandon Y, Tiercy JM, Schanz U et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplant 2006 : 37 : 909 16.
10. Ottinger HD, Ferencik S, Beelen DW et al. Impact of HLA-A, B,C allele mismatches on outcome after unrelated blood stem cell transplantation in whites. Transplantation 2004 : 78 : 1077 80.
11. Kawase T, Morishima Y, Matsuo K et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007 : 110 : 2235 41.
12. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992 : 39 : 225 35.
13. Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 2003 : 62 : 243 50.
14. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004 : 78 : 122 7.
15. Uzunel M, Remberger M, Sairafi D et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006 : 82 : 913 9.
16. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997 : 89 : 3048 54.
17. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998 : 91 : 756 63.
18. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998 : 16 : 2817 24.
19. Casper J, Knauf W, Blau I et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol 2004 : 83 (Suppl 1 S70 1.
20. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999 : 24 : 823 30.
21. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989 : 73 : 1729 34.
22. Ringden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993 : 81 : 1094 101.
23. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003 : 101 : 1620 9.
24. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995 : 15 : 619 25.
25. Hagglund H, Ringden O, Oman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999 : 24 : 831 6.
26. Remberger M, Naseh N, Aschan J et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003 : 32 : 217 23.
27. Ringden O, Labopin M, Gorin NC et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004 : 22 : 416 23.
28. Svahn BM, Remberger M, Myrback KE et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002 : 100 : 4317 24.
29. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001 : 98 : 1739 45.
30. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995 : 15 : 825 8.
31. Ringden O. Management of graft-versus-host disease. Eur J Haematol 1993 : 51 : 1 12.
32. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006 : 81 : 1390 7.
33. Sparrelid E, Hagglund H, Remberger M et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998 : 22 : 795 800.
34. Ljungman P, Lore K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996 : 17 : 583 7.
35. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 : 34 : 1094 7.
36. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 : 53 : 457 81.
37. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999 : 18 : 695 706.
38. Fine J, Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc 1999 : 94 : 496 509.
39. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002 : 99 : 4200 6.
40. Petersdorf EW, Longton GM, Anasetti C et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997 : 89 : 1818 23.
41. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen- presenting cells. Science 1999 : 285 : 412 5.
42. + T-cell responses: the alternative approaches. Annu Rev Immunol 1997 : 15 : 297 322.
43. + T-cell differentiation. J Immunol 1997 : 159 : 5956 63.
44. + T cells by antigenic peptides altered for TCR binding. J Immunol 1997 : 158 : 4237 44.
45. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000 : 38 : 221 34.
46. Zeis M, Uharek L, Hartung G, Glass B, Steinmann J, Schmitz N. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. Hematol J 2001 : 2 : 136 44.
47. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996 : 24 : 71 9.
48. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981 : 304 : 1529 33.
49. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990 : 75 : 555 62.
50. Wetzler M, McElwain BK, Stewart CC et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003 : 17 : 707 15.
51. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.[see comment]. N Engl J Med 2004 : 351 : 2276 85.
52. Eapen M, Rubinstein P, Zhang MJ et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.[see comment]. Lancet 2007 : 369 : 1947 54.